Intralesional Corticosteroid Injections for Alopecia Areata(Kenalog)
Intralesional corticosteroid injections are one of the longest established treatments for localized alopecia areata. The medication most commonly used is triamcinolone acetonide, often referred to by the brand name Kenalog.
Unlike oral or other systemic corticosteroid treatment, intralesional therapy places small amounts of medication directly into areas of active hair loss. The goal is to suppress the local immune and inflammatory activity surrounding susceptible hair follicles while limiting unnecessary systemic exposure.
For adults with limited or moderately extensive patchy alopecia areata, intralesional triamcinolone remains an important first line treatment. It is not a treatment for ordinary male or female pattern hair loss.
Its role also changes as alopecia areata becomes more extensive. In severe alopecia areata, alopecia totalis or alopecia universalis, repeatedly injecting large areas of scalp may become impractical and may not adequately address the overall disease. The availability of FDA approved systemic treatments, including oral JAK inhibitors, has substantially changed management of severe alopecia areata.
What Are Intralesional Corticosteroid Injections?
Corticosteroids suppress inflammatory and immune activity. In alopecia areata, immune activity develops around susceptible hair follicles and disrupts normal hair growth.
Intralesional treatment involves injecting very small amounts of corticosteroid directly into the affected skin rather than exposing the entire body to the doses used with systemic corticosteroid therapy. Triamcinolone acetonide is the corticosteroid used most commonly for this purpose.
Kenalog is a well known brand of triamcinolone acetonide, but the treatment should not be confused with a particular brand name or concentration.
Are Steroid Injections FDA Approved for Alopecia Areata?
Yes, with an important formulation distinction. Kenalog 10, which contains triamcinolone acetonide 10 mg per mL, is FDA approved for intralesional administration in alopecia areata. That makes this different from many medications used in hair loss that are prescribed entirely off label.
However, the Kenalog name is also used for higher concentration products. Kenalog 40 and Kenalog 80 are labeled for intramuscular and intra articular use and their prescribing information specifically states that those formulations are not for intradermal injection.
The fact that products contain the same active ingredient does not mean every formulation or concentration should automatically be treated as interchangeable. Dermatologists treating alopecia areata commonly use triamcinolone concentrations between approximately 2.5 and 10 mg per mL depending on treatment location, disease activity, response and risk of local adverse effects.
The specific concentrations, dilution strategies and injection protocols commonly used in hair loss practice come from clinical studies, guidelines and dermatologic experience rather than from a single FDA established alopecia areata dosing protocol.
How Do Steroid Injections Work in Alopecia Areata?
Alopecia areata is an autoimmune form of nonscarring hair loss. Immune activity directed against susceptible hair follicles disrupts the normal growth cycle.
Intralesional corticosteroids suppress this inflammatory response within the treated area. If the follicle remains viable and the local immune attack is adequately controlled, normal hair production can resume.
The treatment does not permanently eliminate the underlying tendency to develop alopecia areata. It controls immune activity locally.
How Is Alopecia Areata Severity Measured?
The Severity of Alopecia Tool, commonly called SALT, is widely used to estimate the percentage of scalp hair that has been lost. Current international guidance generally considers approximately 1 to 20 percent scalp hair loss limited or mild disease, 21 to 49 percent moderate disease and 50 percent or greater severe disease.
These percentages are useful, but they do not tell the entire story. Loss of eyebrows or eyelashes, rapidly progressive shedding, significant nail involvement, failure to respond to treatment and the psychological impact of visible disease can make alopecia areata more serious than a scalp percentage alone suggests.
This is why treatment decisions should be based on the complete clinical picture rather than simply counting bald patches.
Who Is Most Likely to Benefit?
Intralesional triamcinolone is best established for adults with limited or moderate alopecia areata, particularly patients with discrete scalp patches that can be treated directly. Current British Association of Dermatologists guidance recommends intralesional triamcinolone as a first line option for adults with limited to moderate alopecia areata. It can also be considered for selected eyebrow or beard involvement.
Signs such as exclamation point hairs, black dots, broken hairs or a positive hair pull test can help show that alopecia areata is active. Some observational research suggests that patients with active disease can respond to injections.
However, these findings should not be interpreted to mean that injections are automatically the best treatment for rapidly progressive disease. When hair loss is spreading quickly or becoming diffuse, a broader treatment strategy may be more appropriate.
Are Steroid Injections Used for Severe Alopecia Areata?
Sometimes, but the role changes substantially. Current guidelines consider intralesional triamcinolone in severe alopecia areata on a case by case basis rather than as the default treatment.
Severe disease generally means at least 50 percent scalp hair loss, although eyebrow, eyelash, nail involvement and other clinical factors also matter. Treating very large areas requires many injections and increases cumulative corticosteroid exposure, discomfort and the risk of local tissue atrophy.
In extensive disease, injections may still be useful for selected areas, such as resistant scalp patches, eyebrows or beard involvement, while the overall disease is being managed with another treatment strategy.
What About Alopecia Totalis and Alopecia Universalis?
Intralesional corticosteroids are generally not an efficient primary treatment for alopecia totalis or alopecia universalis. Alopecia totalis involves complete or nearly complete scalp hair loss. Alopecia universalis involves extensive loss of scalp, facial and body hair.
These are widespread manifestations of alopecia areata. Injecting individual sites does not address the full distribution of disease.
The emergence of FDA approved systemic JAK inhibitors has significantly changed treatment options for patients with severe alopecia areata. Baricitinib and deuruxolitinib are approved for adults with severe alopecia areata. Ritlecitinib is approved for adults and adolescents age 12 and older with severe alopecia areata.
Intralesional treatment can still have a selective role, but it should not be presented as the modern default treatment for widespread disease.
What About Diffuse or Rapidly Progressive Alopecia Areata?
Diffuse alopecia areata can produce widespread thinning rather than clearly defined bald patches. It can sometimes resemble telogen effluvium, female pattern hair loss or other causes of diffuse shedding.
Rapidly progressive alopecia areata can also advance faster than individual patches can reasonably be injected. Because intralesional therapy treats specific areas of skin, it becomes less practical as disease becomes broadly distributed or rapidly progressive.
Correct diagnosis and assessment of the pace and extent of disease should come before deciding that injections are the right approach.
How Effective Are Intralesional Steroid Injections?
Intralesional triamcinolone has been used successfully for localized alopecia areata for decades and remains a standard first line treatment in contemporary dermatologic guidelines.
At the same time, it is important to distinguish longstanding clinical experience from the quality of randomized trial evidence. A 2023 Cochrane review found that randomized placebo controlled evidence for intralesional corticosteroids was limited and of very low certainty because relatively few patients had been studied in rigorous placebo controlled trials.
That does not mean the treatment lacks clinical activity. Comparative studies, concentration trials, decades of clinical use and modern guidelines consistently support intralesional triamcinolone for appropriately selected localized disease.
A 2026 systematic review and meta analysis involving 640 patients also found that intralesional triamcinolone was more likely than cryotherapy to produce at least 50 percent hair regrowth in patchy alopecia areata. That is useful comparative evidence, although it should not be interpreted as the same thing as a large modern placebo controlled trial.
The practical conclusion is that intralesional triamcinolone is a well established clinical treatment whose everyday dermatologic use is stronger than the size and quality of the randomized evidence base might suggest.
What Concentration of Triamcinolone Is Used?
There is no single concentration that is appropriate for every patient or treatment site. Current guidelines commonly describe concentrations between approximately 2.5 and 10 mg per mL.
Five mg per mL is a commonly recommended starting concentration for adult scalp alopecia areata. Lower concentrations may be chosen for cosmetically sensitive areas such as the face or eyebrows, where steroid related atrophy can be particularly noticeable.
A higher concentration does not automatically mean a better result.
Does 10 mg per mL Work Better Than 5 mg per mL?
Not necessarily. A retrospective study comparing 5 mg per mL with 10 mg per mL found complete regrowth after three treatment sessions in approximately 44 percent of patients receiving 5 mg per mL and 54 percent receiving 10 mg per mL. The difference was not statistically significant.
A randomized study comparing 2.5, 5 and 10 mg per mL with saline found that all three triamcinolone concentrations produced better regrowth than saline. The 10 mg per mL concentration produced somewhat greater treatment activity, but it also produced the highest rate of skin atrophy and visible small blood vessels.
Interestingly, the investigators suggested beginning with 2.5 mg per mL and increasing treatment according to clinical and dermoscopic response. Current British Association of Dermatologists guidance considers 5 mg per mL a reasonable standard starting concentration in adults.
These differences reinforce an important principle. There is no evidence that every patient should automatically receive the highest concentration available. The objective is adequate local disease control with the lowest effective exposure and acceptable local tolerability.
How Are the Injections Given?
Small quantities of triamcinolone are injected at multiple points across the affected area. Current guidance describes injections spaced evenly within the patch and around its margins, commonly using approximately 0.1 mL per square centimeter.
The exact concentration, total volume, injection depth and spacing depend on the treatment location and physician technique. Treatment is often repeated at intervals of approximately six to twelve weeks, although other schedules have been used in clinical practice and published studies.
The amount injected into any single treatment session matters because increasing the total volume also increases the amount of corticosteroid available for systemic absorption.
How Long Does It Take to See Hair Regrowth?
Hair regrowth is not immediate. Early new hairs may sometimes become visible within several weeks. More meaningful assessment generally requires several treatment cycles.
Studies evaluating patients over 12 to 24 weeks show that some respond relatively quickly while others require several months. A lack of visible growth after one treatment does not necessarily mean the treatment has failed.
At the same time, injections should not continue indefinitely when there is no objective evidence of improvement. If meaningful regrowth has not occurred after several months, the diagnosis, disease activity and overall treatment strategy should be reconsidered.
How Should Progress Be Measured?
Repeated treatment should ideally be accompanied by objective monitoring. Standardized photographs taken under consistent lighting and positioning can help document regrowth and identify new areas of loss.
For patients with more extensive scalp involvement, SALT scoring provides a standardized way to quantify changes in scalp hair loss over time. Trichoscopy can also document disease activity and changes in the follicular population.
This is more useful than relying on memory or casual visual impressions after months of treatment.
Do the Injections Hurt?
They can. Multiple injections are generally required across each treated patch, so discomfort is one of the practical limitations of treatment.
Pain varies with the size and location of the treatment area and individual sensitivity. Topical anesthetics, cooling, cold spray, vibration and other distraction techniques may reduce discomfort.
Pain becomes particularly important when considering repeated treatment in children.
What Are the Most Common Side Effects?
The most important adverse effects are usually local. They include pain during injection, minor bleeding or bruising, temporary skin thinning, depression of the skin, loss of subcutaneous fat, visible small blood vessels, changes in skin pigmentation, local irritation, and occasionally folliculitis or acne like changes.
Skin and fat atrophy deserve particular attention. These effects depend on concentration, total amount injected, injection depth, treatment interval and repeated treatment of the same area.
Pigment changes can also be especially noticeable in patients with darker skin tones. Current guidelines specifically recommend counseling patients with Fitzpatrick skin types V and VI about the possibility of corticosteroid related depigmentation or other pigmentary changes.
Can Steroid Injections Cause Permanent Skin Atrophy?
Most corticosteroid related atrophy after appropriately administered intralesional treatment improves over time. Recovery can take months.
However, prolonged or occasionally persistent tissue changes can occur, particularly when excessive concentrations are used, injections are placed too superficially or the same area is repeatedly treated despite existing atrophy.
If a visible depression develops, continuing to inject directly into that area can make the problem worse. Technique matters just as much as the medication itself.
Can the Steroid Be Absorbed Systemically?
Yes. Intralesional treatment is intended to concentrate corticosteroid activity within the treated skin, but it does not mean systemic absorption is impossible.
Kenalog prescribing information specifically notes that larger total injection volumes make more corticosteroid available for systemic absorption and systemic effects. With limited scalp treatment and appropriate doses, clinically significant systemic corticosteroid effects appear to be uncommon.
However, rare systemic effects, including adrenal suppression and Cushing syndrome, have been reported after intralesional triamcinolone, particularly with substantial cumulative exposure or in children.
Risk becomes more relevant when larger areas are treated, larger doses are used repeatedly or a patient is receiving corticosteroids through more than one route. Localized treatment should therefore not be confused with zero systemic exposure.
Can Steroid Injections Affect Blood Sugar?
They can. Systemic corticosteroid exposure can increase blood glucose. This is much less likely after small localized intralesional doses than after systemic corticosteroid therapy, but it is not impossible.
Significant hyperglycemia has been reported after intralesional triamcinolone in susceptible patients. People with diabetes should make sure the treating physician knows about the condition and should discuss whether additional glucose monitoring is appropriate around treatment.
Are There Important Drug Interactions?
Yes. Even though the medication is injected locally, systemic interactions can become relevant if enough triamcinolone is absorbed.
Strong inhibitors of the CYP3A4 enzyme can increase corticosteroid exposure. Examples include ritonavir and cobicistat, which are used in certain antiviral regimens, as well as some azole antifungal medications and certain other drugs.
Patients should provide a complete medication list before receiving repeated intralesional corticosteroid treatment. A physician should not assume that an injectable scalp treatment is pharmacologically isolated from the rest of a patient’s medications.
Can an Area With an Infection Be Injected?
No. Corticosteroids suppress immune and inflammatory activity. Intralesional corticosteroid treatment should not be administered into an area with an active local infection.
Sterile technique is essential during the procedure. Patients should also tell the physician about significant systemic infections or immune suppression before treatment.
Can Steroid Injections Cause an Allergic Reaction?
Rarely. Serious hypersensitivity reactions, including anaphylaxis, have been reported with injectable triamcinolone.
This is uncommon, but it is another reason treatment should be performed in an appropriate medical setting rather than viewed as a routine cosmetic injection.
Can Steroid Injections Be Used in the Eyebrows?
Yes, in selected patients. Intralesional triamcinolone can be useful for eyebrow alopecia areata.
Lower concentrations are generally favored because eyebrow and facial skin are thinner and corticosteroid related atrophy can be particularly noticeable. Treatment near the eye requires additional expertise.
Corticosteroid injections around the eye have been associated with rare but potentially serious ocular complications, including increased intraocular pressure, cataract and other visual complications. Rare retinal complications have also been reported after corticosteroid injections involving the scalp and eyebrow region.
Eyebrow treatment should therefore be performed by a physician who understands the anatomy and specific risks of periocular injection. Intralesional injections are not ordinarily used to inject the eyelid margin for eyelash alopecia areata.
Can Steroid Injections Be Used for Beard Alopecia Areata?
Yes. Localized beard alopecia areata can respond to intralesional triamcinolone.
Facial skin is more cosmetically sensitive than much of the scalp, so concentration and technique require additional care. The possibility of skin depression, fat atrophy and pigment change should be discussed before treatment.
Can Children Receive Steroid Injections?
Sometimes. Current guidelines consider intralesional triamcinolone on a case by case basis for older children and adolescents with limited or moderate alopecia areata.
Pain and fear of repeated injections are major practical considerations. The risk of skin atrophy also remains important.
Kenalog 10 contains benzyl alcohol, and corticosteroid exposure deserves additional caution in pediatric patients because systemic exposure can have greater consequences in a developing child. For younger children, potent topical corticosteroids are often more practical as an initial approach.
The decision should take into account the extent of disease, age, cumulative corticosteroid exposure, ability to tolerate injections and the psychological experience of repeated procedures.
What About Pregnancy?
Pregnancy should be disclosed to the treating physician before intralesional corticosteroid treatment. Adequate controlled pregnancy studies of intralesional triamcinolone for alopecia areata are not available.
Corticosteroids can produce developmental effects in animal studies, and current prescribing information advises use during pregnancy only when the potential benefit justifies the potential risk.
This does not mean that every localized injection during pregnancy has been shown to cause fetal harm. It means pregnancy changes the risk benefit calculation for an elective hair loss treatment.
The physician should consider disease severity, treatment area, expected total exposure and available alternatives.
What About Breastfeeding?
Breastfeeding should also be discussed with the treating physician. Systemically administered corticosteroids can enter human milk.
The amount of systemic exposure after limited intralesional treatment is generally expected to be much lower than with systemic corticosteroid therapy, but the actual exposure depends on total dose and treatment area.
There is no reason to assume that intralesional treatment automatically means zero systemic exposure. The decision should be individualized.
Can Alopecia Areata Come Back After Successful Injections?
Yes. Intralesional corticosteroids suppress active disease in treated follicles. They do not permanently eliminate the autoimmune tendency responsible for alopecia areata.
In the retrospective study comparing 5 and 10 mg per mL triamcinolone, recurrence occurred in approximately 45 percent of patients during one to three years of follow up.
Relapse does not mean the injections caused the disease to return. It reflects the relapsing and remitting nature of alopecia areata.
Do Steroid Injections Cure Alopecia Areata?
No. Intralesional corticosteroids can suppress local immune activity and allow follicles to resume hair production.
Some patients experience prolonged remission. Others relapse in the same area or develop new patches elsewhere.
Treatment success should therefore be understood as regrowth and disease control rather than permanent elimination of the underlying disease.
Are Steroid Injections Used for Other Types of Hair Loss?
Sometimes, but the diagnosis matters enormously. Dermatologists also use intralesional corticosteroids in selected inflammatory scalp disorders, including certain scarring alopecias.
In those diseases, the objective may be to suppress inflammation and prevent additional permanent follicular destruction rather than simply stimulate regrowth. The dosing, treatment intervals and response expectations used for alopecia areata should not automatically be applied to scarring alopecias.
There is no established role for intralesional corticosteroid injections in ordinary male or female pattern hair loss unless a separate inflammatory scalp disorder is also present.
Injecting corticosteroids into a scalp simply because hair is thinning can expose a patient to unnecessary risk without treating the underlying problem.
How Have JAK Inhibitors Changed the Role of Steroid Injections?
Intralesional corticosteroids have not become obsolete. They remain one of the most useful treatments for localized alopecia areata.
What has changed is the treatment of severe disease. Several oral JAK inhibitors are now FDA approved for severe alopecia areata. These therapies can address disease throughout the scalp and body rather than one injected area at a time.
For limited patchy disease, exposing the entire body to systemic immunomodulatory therapy may not be necessary when localized treatment is effective. For severe disease, repeatedly injecting very large scalp areas may no longer represent the most rational primary strategy.
The extent, activity, speed of progression, age and overall impact of the disease should determine the treatment approach.
The AHLA Perspective
Intralesional triamcinolone remains one of the most established and useful treatments for localized alopecia areata. Unlike many medications used in hair loss, Kenalog 10 is specifically FDA approved for intralesional treatment of alopecia areata.
That does not mean every concentration, formulation or injection protocol is interchangeable. It also does not mean that more corticosteroid produces better treatment.
Modern evidence supports using enough medication to control local disease while minimizing the risk of skin and fat atrophy, pigment change and unnecessary systemic exposure. Higher concentrations can increase local adverse effects without guaranteeing meaningfully better regrowth.
Steroid injections also need to be placed in the context of the disease being treated. A few localized patches of alopecia areata are very different from severe disease affecting most of the scalp. The availability of FDA approved systemic treatments has made that distinction even more important.
There is also an important difference between an established clinical treatment and the strength of its randomized trial evidence. Intralesional triamcinolone has decades of dermatologic experience and remains strongly recommended in modern guidelines for localized disease, even though the high quality placebo controlled evidence base is smaller than many consumers might expect.
Most importantly, corticosteroid injections should not be used simply because someone is losing hair. The diagnosis comes first.
Alopecia areata, male and female pattern hair loss, telogen effluvium and inflammatory scarring alopecias are different conditions and require different strategies.
The objective is not to inject every area where hair is missing. It is to establish the diagnosis, identify active disease, determine whether localized corticosteroid treatment makes sense, document whether the patient is actually responding and use the lowest effective exposure necessary to control the disease while protecting the skin and remaining follicles.
Used for: Alopecia Areata
Selected References
- U.S. National Library of Medicine. Kenalog 10, Triamcinolone Acetonide Injection: Full Prescribing Information. Includes FDA approved intralesional use for alopecia areata, administration, systemic absorption, infection precautions, pregnancy, lactation, drug interactions and local tissue atrophy. DailyMed Prescribing Information
- U.S. National Library of Medicine. Kenalog 40 and Kenalog 80, Triamcinolone Acetonide Injection: Full Prescribing Information. These formulations are labeled for intramuscular and intra articular use and are not for intradermal injection. DailyMed Prescribing Information
- Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists Living Guideline for Managing People With Alopecia Areata 2025. British Journal of Dermatology. 2026;194:e56 to e73. doi:10.1093/bjd/ljaf452. PubMed
- Chu TW, AlJasser M, Alzolibani A, et al. Identification of a Novel Step Up Regimen of Intralesional Triamcinolone Acetonide in Scalp Alopecia Areata Based on a Double Blind Randomized Controlled Trial. Journal of Dermatological Treatment. 2022;33:1922 to 1929. doi:10.1080/09546634.2020.1849129. PubMed
- Muhaidat JM, AlJamal M, AlMomani N, et al. A Retrospective Comparative Study of Two Concentrations of Intralesional Triamcinolone Acetonide in the Treatment of Patchy Alopecia Areata on the Scalp. Clinical, Cosmetic and Investigational Dermatology. 2020;13:795 to 803. PubMed
- Mateos Haro M, Novoa Candia M, Sánchez Vanegas G, et al. Treatments for Alopecia Areata: A Network Meta Analysis. Cochrane Database of Systematic Reviews. 2023;10:CD013719. doi:10.1002/14651858.CD013719.pub2. PubMed
- Albarari SSA, Aisidat TA, Musleh A, Edpuganti S. Treatment Outcomes of Triamcinolone Acetonide Compared With Cryotherapy in Alopecia Areata: Evidence From a Systematic Review and Meta Analysis. Dermatology Practical & Conceptual. 2026;16:6092. doi:10.5826/dpc.1601a6092. PubMed